Investments 投资
Details of our portfolio appear below.
以下是我们的投资组合的详细信息：
Acrobot 公司
Acrobot is a spin-out from Imperial College London. The founders included Brian Davis, Professor of Medical Robotics in the Department of Mechanical Engineering at Imperial College London and Justin Cobb, Professor of Orthopaedics at Imperial College London. Professor Cobb is civilian adviser in orthopaedics to the Royal Air Force, on the staff of King Edward VII Hospital, and is orthopaedic surgeon to the Royal Household. The Company’s products and services centre on the application of computer science, mechanical, electrical, and electronics engineering disciplines to surgery. The early focus of the Company was on the development of hands-on robotic solutions and this work ultimately led to the evolution of the Acrobot Modeller, Acrobot Planner and Acrobot Navigator products. Following a funding round in July 2007, Acrobot has moved forward fully to commercialise its Modeller, Planner and Navigator products in orthopaedics and to accelerate development of its exciting bone sculpting robotic solution, Acrobot Sculptor®. The Acrobot Sculptor® system is a motorised programmable device based on Acrobot’s key ‘Active Constraint’ patented technology, which prevents the surgeon accidentally moving a bone cutting tool outside a specified area. LTF first co-led a syndicate investing in Acrobot in July 2007 and has subsequently co-led the syndicate in providing follow-on funding. This syndicate has now invested over £3m. Acrobot was recognised by the English Tech Tour as one of the most promising high growth early- and expansion-stage technology companies in the country, being named as one of 24 winners chosen from a pool of nearly 300 candidates. Acrobot’s systems are used in Charing Cross Hospital, King Edward VII’s Hospital Sister Agnes, The London Clinic, and the Royal Bournemouth Hospital.
Acrobot公司是由伦敦帝国理工学院分离出来的一家公司，其创始人包括帝国理工学院机械工程系医学机器人专业的布莱恩·戴维斯教授（Brian Davis）和骨科专业的贾斯汀·科布教授（Justin Cobb）。贾斯汀·科布教授（Justin Cobb）是皇家空军的民间骨科顾问、国王爱德华七世医院的医生并且是皇室家庭的矫形外科医生。Acrobot公司的产品和服务主要围绕计算机科学、机械工程、电气工程和电子工程等学科在外科领域的应用。公司早期专注发展实际操作的机器人解决方案，此后不断改进Acrobot Modeller、Acrobot Planner和Acrobot Navigator等产品。Acrobot公司在2007年7月完成了一轮募资后开始逐步将其在骨科领域的Modeller、Planner和Navigator产品推向市场，并加快了其令人振奋的骨头塑形机器人解决方案Acrobot Sculptor®产品的开发步伐。Acrobot Sculptor®系统是基于Acrobot公司的核心专利“主动约束”技术开发的一种马达化的可编程装置，能够防止外科医生在使用骨头切割工具时不小心切到了规定切割区域以外的其他地方。伦敦技术基金于2007年7月联合率领一个财团对Acrobot公司进行第一轮投资。此后，又领导该财团对Acrobot进行了后续投资。迄今为止，该财团共向Acrobot公司投资300多万英镑。《英国科技巡览》杂志（English Tech Tour）从大约300家公司中选出了24家英国最有前途、处于早期扩展阶段并且高速发展的技术公司，Acrobot公司就是其中之一。查令十字医院（Charing Cross Hospital）、国王爱德华七世医院艾格尼斯（Agnes）修女分院、伦敦诊所（London Clinic）和皇家伯恩茅斯（Bournemouth）医院现已采用了Acrobot公司开发的系统。
For more information, please see latest news, our press release and www.acrobot.co.uk.
欲知更多详情，请见公司最新消息, 新闻公告或登陆网站: www.acrobot.co.uk。
ApplianSys 公司
ApplianSys specialises in server appliances, taking the central role in designing and building the appliance. Server appliances are servers with hardware and software designed and integrated for a specific task in a network. The server appliance approach offers a number of customer benefits compared with installing standard software applications on general purpose servers. These benefits include reduced costs of ownership and enhanced security. Savings are derived from lower upfront configuration and downstream maintenance costs, as well as lower costs associated with space, power and heat. With server appliances dedicated to one application the platform is also inherently secure. The London Technology Fund co-led a funding round of £620k in January 2007. A second close on 28 February 2007 took the total amount raised by ApplianSys to £720k.
ApplianSys是一家专业从事专用服务器研发的公司，在设计和建立专用服务器方面扮演着重要角色。专业服务器是指配有为网络中特定任务而设计、整合的软硬件的服务器。与安装了标准软件应用的通用服务器相比，专用服务器能给客户带来几个好处，其中包括降低拥有成本、提高安全性。客户能通过减少预设配置成本、减少下游维护成本和与空间、电能和供暖相关的成本而节约开销。由于专用服务器专门针对某一应用，所以此类平台本身是安全的。伦敦技术基金于2007年1月共同参与领导了一个投资财团向该公司注资62万英镑。2007年2月28日对该公司进行的第二轮投资使ApplianSys公司的总筹资金达到72万英镑。
For more information, please see latest news, our press release and www.appliansys.com.
欲知更多详情，请见公司最新消息, 新闻公告或登陆网站: www.appliansys.com。
deltaDOT 公司
deltaDOT Ltd is a life science company that is developing and commercialising innovative enabling technologies for the separation and analysis of biomolecules. It was founded in 2000 and is a spin out from Imperial College London. deltaDOT's core label free analysis technology, coupled with proprietary software algorithms, forms the technical basis of its products. This label free technology enables higher quality and faster separations compared to existing technologies. The increased performance enables the direct monitoring of unlabelled biomolecules, reducing the cost per analysis compared to conventional methods. deltaDOT addresses biomolecular separation applications within pharmaceutical, biotechnology, biodefence, food and drink quality, forensic science, diagnostic and academic markets. The London Technology Fund participated in a funding round of £6m in March 2006. The company has subsequently announced its participation in a US$11m Phase 2 contract for the US Defense Threat Reduction Agency (DTRA) – Joint Science and Technology Office, Transformational Medical Technologies Initiative (TMTI) to develop technology for accelerated monoclonal antibody and vaccine manufacturing. This contract followed the successful completion of the 12-month Phase 1 contract awarded by the US Defense Advanced Research Projects Agency (DARPA). This was followed by the announcement of a joint venture operation with the Qatar Science and Technology Park, to be based in Qatar.
deltaDOT有限公司是一家生命科学公司，专门开发用于生物分子的分离和分析的创新技术并且把这些技术商业化。deltaDOT公司于2000年创立，是伦敦帝国理工学院分离出来的公司。该公司的核心是无标记分析技术和专有软件算法，两者共同构成了公司产品的技术基础。与现有的技术相比，无标记技术能够提高分离质量，加快分离速度。与传统技术相比，采用该公司的技术能够达到更好的分离效果，直接监测未标记的生物分子，这样就能降低每次分析的成本。公司的产品主要用于制药行业、生物技术、生物防卫、餐饮品质鉴定、司法科学、诊断和学术领域市场的生物分子分离。伦敦技术基金参与了该公司2006年3月的一轮投资，总额为600万英镑。随后，该公司宣布与美国国防威胁降低署（DTRA）签订第二期合同，合同价值达1100万美元，内容是与科学和技术联合办公室、转型医疗技术计划（TMTI）一起开发单克隆抗体和疫苗的制造技术。在此之前，deltaDOT公司已成功履行了与美国国防部高级研究计划管理署（DARPA）签订的为期12个月的第一期合同。签订第二期合同后，该公司宣布与卡塔尔科技园协作成立一家合资企业，总部将设在卡塔尔。
For more information, please see latest news, our press release and www.deltadot.com.
欲知更多详情，请见公司最新消息, 新闻公告或登陆网站: www.deltadot.com。
Dexela 公司
Dexela is a developer of innovative technologies for fast, low-dose X-ray imaging. Formed in 2004, it pioneered developments in tomosynthesis, an advanced imaging technique focused on the early detection of breast cancer. In 2009, Dexela launched a family of flat panel CMOS X-ray detectors ideally suited to breast tomosynthesis and a range of other applications including mammography, fluoroscopy, dental CBCT, cardiology, angiography, bone densitometry and non-destructive testing (NDT). Dexela’s CMOS X-ray detectors combine unprecedented speed and superior image quality with value and reliability. LTF invested in Dexela in July 2008 as part of a syndicate, including Albion Ventures, which invested over £2.6m in aggregate. In 2008 Dexela won the International Innovation Category at the 2008 London Passport to Export Awards. It has subsequently announced a collaboration agreement with the Italian company IMS S.R.L. and a strategic partnership with the Californian software company, Three Palm Software. In 2010 it signed a distribution agreement with the Chinese company, Titan Electro-Optics Co Ltd, with a focus on the non-medical applications for Dexela’s innovative technology.
Dexela是一家专业开发快速、辐射剂量低的X射线成像创新技术的公司。Dexela公司成立于2004年，是X射线断层分析技术（一种用于乳腺癌的早期检测的高级成像技术）的先驱者。2009年，Dexela公司推出了一组平板CMOS X射线检测装置，非常适用于乳房层析和其他的一系列应用，其中包括乳房成像、荧光透视检查、牙科电脑断层摄影、心脏扫描、血管成像、骨密度测定和无损试测（NDT）。Dexela公司的CMOS X射线检测装置将前所未有的高速度、一流的影像画质与卓越的经济性和可靠性完美结合起来。伦敦技术基金作为一个投资财团的成员（其他成员还包括Albion Ventures公司）于2008年7月投资给Dexela公司，整个财团的总投资达260多万英镑。2008年，Dexela公司赢得2008伦敦出口通行证奖的国际创新类大奖。此后，Dexela宣布与意大利的IMS S.R.L.公司签订合作协议并与加利福尼亚的三棕榈软件公司（Three Palm Software）建立战略伙伴关系。2010年，Dexela与中国的先锋科技股份有限公司签订经销协议，重点是推广Dexela公司的创新技术在非医疗领域的应用。
For more information, please see latest news, our press release and www.dexela.com.
欲知更多详情，请见公司最新消息, 新闻公告或登陆网站: www.dexela.com。
Dynamic IT Management Services -动态信息技术管理服务公司
Dynamic IT Management Services is a supplier of specialist software for the global foreign exchange market. Dynamic is based in London, which is the world’s largest centre of foreign exchange activity. The company has developed a trade notification product, TradeSTP, which enables banks and brokers to deliver foreign exchange trade notifications directly to their clients’ applications. This system of ‘straight through processing’ offers enhanced speed and accuracy by eliminating the delay and risk of error associated with manual updating. TradeSTP has the potential to be a key component of the service offered to foreign exchange clients by banks and brokers. The company’s subsidiary, Logicscope, was voted the Best Post-Trade Services (Non-Bank Provider) in 2008 and 2009 in the annual Profit and Loss Digital Markets Awards. The London Technology Fund led a funding round of £800k in 2006 and has subsequently announced a partial exit.
动态信息技术管理公司是全球外汇市场专用软件的专业供应商，总部设在全球外汇活动最活跃的城市伦敦。该公司开发了一款交易通知产品TradeSTP，银行和经纪公司可利用该产品将外汇交易通知直接发送到客户的应用程序上。这种“直达式处理”系统消除了手动更新可能带来的延迟和差错风险，从而提高了通知的速度和准确性。因此，TradeSTP有可能成为银行和经纪公司提供给他们外汇交易客户的服务的关键组成部分。该公司的子公司Logicscope公司获得了2008年最佳交易后服务（非银行机构）大奖和2009年度损益数字市场大奖。伦敦技术基金于2006年向该公司注资80万英镑，不过此后宣布退出部分投资。
For more information, please see latest news and our press release.
欲知更多详情，请见公司新闻公告。
Immune Targeting Systems 免疫目标公司
Immune Targeting Systems (ITS) Ltd is a London-based biotech company developing synthetic vaccines for mutating viruses. The company’s lead programme is a synthetic universal influenza vaccine targeting all potential seasonal and pandemic flu strains. The thermostable vaccine potentially offers a new concept in flu vaccine supply and could represent a major breakthrough for governments wishing to create long-term vaccine stockpiles. Candidates for Hepatitis-B & C, HIV, and HPV-cancer await development funding or partners and the vaccine platform is applicable to a host of other infectious diseases as well as cancers. The London Technology Fund participated in ITS’s first significant funding round of £4.5m in July 2007 and a further funding round of up to £8.65m in February 2010. The second funding round will enable the progress of ITS’s lead candidate FP-01 through to the completion of phase II proof of concept efficacy studies. LTF was the only UK investor in an international syndicate including Novartis Venture Fund (Switzerland), HealthCap (Sweden) and Truffle Capital (France).
免疫目标公司是一家设在英国的生物技术企业，专门开发针对变异病毒的人工合成疫苗。该公司的主导项目是一种人工合成的通用流感疫苗，适用于所有潜在的季节性和流行性流感。这种热稳定性高的疫苗很可能成为流感疫苗供应的新理念。同时，对于那些希望建立长期疫苗储备的政府来说，该疫苗很可能成为一项重大突破。针对乙型肝炎和丙型肝炎、艾滋病和人乳头瘤病毒（HPV）癌症的疫苗还在等待开发资金的注入和寻找合作方，并且该疫苗的平台同时适用于其他许多传染性疾病和癌症。伦敦技术基金于2007年7月在免疫目标公司融资的第一轮中投入了450万英镑，并且在2010年2月的第二轮中投入865万英镑。第二轮融资后，公司将能够完成其主导的候选疫苗FP-01第二阶段的概念验证疗效研究。伦敦技术基金是对免疫目标公司投资的国际财团中唯一的英国投资方，财团中的其他成员有瑞士的Novartis 创投资本（Novartis Venture Fund）、瑞典的HealthCap集团和法国的Truffle资本。
For more information, please see latest news, our press release and www.its-innovation.co.uk.
欲知更多详情，请见公司最新消息, 新闻公告或登陆网站: www.its-innovation.co.uk。
Intellistream 公司
Intellistream developed a platform for deploying interactive mobile video applications. This platform, Unistream™, was initially developed to operate over the video calling feature built into all 3G handsets, but was expanded to cover IP-based smart-phone handsets (such as those which can use both 2.5G or 3G networks) via a downloaded client. The Company initially targeted the security and safety market offering remote access to CCTV cameras from mobile phones. Possible applications included the corporate security markets, both SME businesses and also as an adjunct to existing large corporate and public security installations, and the domestic security markets. Additionally the Company's technology could be applied to a number of other applications including participation TV and gaming. The London Technology Fund led a funding round of £355k in November 2006. In April 2008 LTF announced the first close of a further funding round of up to £1m and this was followed by the appointment of a new chairman. In early 2010 the company reached a royalty agreement and completed the associated disposal of its assets.
Intellistream公司为交互式移动视频的部署开发了一个平台，即Unistream™平台。该平台最初用于3G手机内嵌的视频通话功能，但通过下载客户端，现在该平台可在所有基于IP技术的智能手机上得以应用（比如那些即可以用2.5G又可以用3G网络的手机）。该公司的产品最初是针对安全市场，是让手机能够远程连接闭路电视摄像机。潜在应用领域包括公司安全市场，即适用于中小企业，也适用于大型企业和公共安全装置以及国内保安市场。此外，Intellistream的技术还可以用于很多其他领域，包括观众参与式电视节目和游戏市场。伦敦技术基金2006年11月牵头为该公司募资，募集到35.5万英镑。2008年4月，伦敦技术基金的新董事长上任，宣布再次向Intellistream公司投资100万英镑。2010年初，Intellistream签署了技术使用费协议并且完成了相关的资产处置事项。
For more information, please see latest news and www.intellistream.co.uk.
欲知更多详情，请见公司最新消息或登陆网站: www.intellistream.co.uk。
Novacem 公司
Novacem, a spin-out from Imperial College London, is developing a cement which has the potential to transform the cement industry from being a significant emitter of CO2 to being an absorber of CO2. The annual production of over 2.5 billion tonnes of conventional Portland cement is already responsible for 5% of global CO2 emissions, and cement volumes are expected to double by 2050. In contrast to Portland cement, Novacem cement absorbs more CO2 over its life cycle than it emits. Novacem estimates that for every tonne of ordinary Portland cement replaced by Novacem cement, around 0.75 tonne of CO2 could be captured and stored indefinitely in construction products. In August 2009, LTF announced it was joint lead in a syndicate which included Imperial Innovations Group plc and the Royal Society Enterprise Fund, together investing over £1m. In March 2010 Novacem was selected from hundreds of companies across the world to be recognised as one of five New Energy Pioneers at the Bloomberg New Energy Finance Summit, based on an assessment of its innovation, traction and potential. In April 2010 it was announced that Novacem was named as one of the top 10 Emerging Technology companies by MIT’s Technology Review. Each year, MIT’s Technology Review selects what it believes are the 10 most important emerging technologies worldwide. In July 2010 Novacem announced that it had attracted Lafarge as the first subscriber to its "Green Cement Bond", an innovative commercial and financial approach for engagement with major cement manufacturers to accelerate the development of Novacem’s carbon negative cement.
Novacem公司是由伦敦帝国理工学院分离出来的一家公司。该公司正在开发一种新水泥，而且可能因此将水泥工业从二氧化碳排放大户转变为二氧化碳的吸收行业。传统的普通水泥全球年产量达到25亿多吨，所带来的二氧化碳排放占全球总量的5%，并且水泥的产量预计到2050年还会翻倍。与普通水泥相反，在使用Novacem公司的水泥过程中，所吸收的二氧化碳量会超过排放量。Novacem公司估计每使用1吨Novacem水泥取代等量的普通水泥，就能把捕捉0.75吨二氧化碳并把这些二氧化碳永久储存在建筑产品中。2009年8月，伦敦技术基金宣布联手帝国创新集团（Imperial Innovations Group plc）和皇家学会企业基金（Royal Society Entreprise Fund）参与的投资财团向Novacem投资100多万英镑。2010年3月，Novacem经过对创新能力、发展势头和潜力的评估，从全球数百家企业中脱颖而出 ，在Bloomberg新能源金融峰会（Bloomberg New Energy Finance Summit）上成为5家被选出的新能源先驱公司中的一个。2010年4月，Novacem公司被麻省理工学院《科技创业》评选为全球10佳新兴技术公司。麻省理工学院《科技创业》每年从全球选出10项被认为最为重要的新兴技术。Novacem公司于2010年7月宣布，拉法基成为了第一家认购Novacem公司“绿色水泥债券”的公司。“绿色水泥债券”是一种创新的商业和财务做法，旨在让主要的水泥生产商参与进来，加速发展Novacem公司的负碳水泥。
For more information, please see latest news, our press release and www.novacem.com.
欲知更多详情，请见公司最新消息, 新闻公告或登陆网站: www.novacem.com。
Please be sure to read this important legal information.
请务必认真阅读这些重要的法律信息。